Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Platinum-Resistant Fallopian Tube Carcinoma”

163 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 163 results

Early research (Phase 1)Looking for participantsNCT05691504
What this trial is testing

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Who this might be right for
Advanced Endometrial CarcinomaMetastatic Endometrial CarcinomaMetastatic Fallopian Tube Carcinoma+8 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Study completedNCT03657043
What this trial is testing

Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Seagen Inc. 98
Large-scale testing (Phase 3)Study completedNCT00262990
What this trial is testing

Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Neoplasms
Novartis Pharmaceuticals 829
Early research (Phase 1)Study completedNCT00059618
What this trial is testing

PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
M.D. Anderson Cancer Center 21
Testing effectiveness (Phase 2)Ended earlyNCT01962948
What this trial is testing

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Recurrent Fallopian Tube CancerRecurrent Ovarian Epithelial CancerRecurrent Primary Peritoneal Cavity Cancer
Fox Chase Cancer Center 12
Testing effectiveness (Phase 2)Study completedNCT02312245
What this trial is testing

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Mayo Clinic 13
Testing effectiveness (Phase 2)UnknownNCT03430700
What this trial is testing

Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
University College, London 28
Large-scale testing (Phase 3)Active Not RecruitingNCT05257408
What this trial is testing

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

Who this might be right for
Ovarian NeoplasmFallopian Tube NeoplasmsPeritoneal Neoplasms
Corcept Therapeutics 381
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Testing effectiveness (Phase 2)Ended earlyNCT03311334
What this trial is testing

DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors

Who this might be right for
Renal Cell Carcinoma (RCC)Urothelial CarcinomaPrimary Peritoneal Cancer+3 more
Sumitomo Pharma America, Inc. 47
Testing effectiveness (Phase 2)Study completedNCT00853307
What this trial is testing

MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

Who this might be right for
Ovarian Carcinoma
Millennium Pharmaceuticals, Inc. 31
Not applicableUnknownNCT01372787
What this trial is testing

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Who this might be right for
AnxietyFatigueNausea and Vomiting+20 more
Gynecologic Oncology Group 103
Large-scale testing (Phase 3)Study completedNCT01196741
What this trial is testing

Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
University College, London 107
Testing effectiveness (Phase 2)WithdrawnNCT06393751
What this trial is testing

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Who this might be right for
Platinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal Carcinoma+20 more
National Cancer Institute (NCI)
Large-scale testing (Phase 3)Ended earlyNCT01281254
What this trial is testing

AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)

Who this might be right for
Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
Amgen 223
Testing effectiveness (Phase 2)UnknownNCT02188550
What this trial is testing

Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer

Who this might be right for
Ovarian CancerEndometrial Cancer
Sinai Hospital of Baltimore 20
Large-scale testing (Phase 3)Looking for participantsNCT06855069
What this trial is testing

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

Who this might be right for
Ovarian Cancer
Hansoh BioMedical R&D Company 468
Testing effectiveness (Phase 2)Active Not RecruitingNCT02101775
What this trial is testing

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Ovarian Brenner TumorOvarian CarcinosarcomaOvarian Clear Cell Cystadenocarcinoma+9 more
National Cancer Institute (NCI) 124
Testing effectiveness (Phase 2)Study completedNCT00466960
What this trial is testing

Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy

Who this might be right for
Brenner TumorFallopian Tube CancerOvarian Clear Cell Cystadenocarcinoma+9 more
University of Washington 21
Large-scale testing (Phase 3)Looking for participantsNCT06161025
What this trial is testing

Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Who this might be right for
Solid Cancer
Daiichi Sankyo 860
Load More Results